Summary
2.1000 0.0400(1.9417%)09/13/2024
Opgen Inc (OPGN)
Opgen Inc (OPGN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.9615 | 7.6923 | -1.9791 | -15.6627 | 303.6909 | 850.2262 | -73.7500 | -99.9134 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 2.1000 | |
| Open | 2.0600 | |
| High | 2.2500 | |
| Low | 2.0600 | |
| Volume | 2,548 | |
| Change | 0.0200 | |
| Change % | 0.9615 | |
| Avg Volume (20 Days) | 2,393 | |
| Volume/Avg Volume (20 Days) Ratio | 1.06 | |
| 52 Week Range | 0.19 - 4.73 | |
| Price vs 52 Week High | -55.60% | |
| Price vs 52 Week Low | 1,005.26% | |
| Range | 1.9417 | |
| Gap Up/Down | -0.0200 | |
Fundamentals | ||
| Market Capitalization (Mln) | 17 | |
| EBIDTA | -16,949,472 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 3.0000 | |
| Book Value | 0.2670 | |
| Earnings Per Share | -6.2500 | |
| EPS Estimate Current Quarter | -0.4300 | |
| EPS Estimate Next Quarter | -0.2500 | |
| EPS Estimate Current Year | -10.3700 | |
| EPS Estimate Next Year | -0.2900 | |
| Diluted EPS (TTM) | -6.2500 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -5.1009 | |
| Return on asset (TTM) | -0.4491 | |
| Return on equity (TTM) | -3.1492 | |
| Revenue TTM | 3,070,231 | |
| Revenue per share TTM | 0.5480 | |
| Quarterly Revenue Growth (YOY) | 0.5580 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -8,990,133 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.0118 | |
| Revenue Enterprise Value | 6.6189 | |
| EBITDA Enterprise Value | -0.9064 | |
| Shares | ||
| Shares Outstanding | 12,624,900 | |
| Shares Float | 9,690,488 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.07 | |
| Insider (%) | 5.15 | |
| Institutions (%) | 4.76 | |
08/21 12:52 EST - investorplace.com
OPGN Stock Earnings: OpGen Reported Results for Q2 2024
OpGen (NASDAQ: OPGN ) just reported results for the second quarter of 2024. OpGen reported earnings per share of -$1.18.
OPGN Stock Earnings: OpGen Reported Results for Q2 2024
OpGen (NASDAQ: OPGN ) just reported results for the second quarter of 2024. OpGen reported earnings per share of -$1.18.
06/05 09:53 EST - investorplace.com
OPGN Stock Earnings: OpGen Meets Revenue for Q4 2023
OpGen (NASDAQ: OPGN ) just reported results for the fourth quarter of 2023. OpGen reported earnings per share of -$17.67.
OPGN Stock Earnings: OpGen Meets Revenue for Q4 2023
OpGen (NASDAQ: OPGN ) just reported results for the fourth quarter of 2023. OpGen reported earnings per share of -$17.67.
05/24 16:05 EST - globenewswire.com
OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q
ROCKVILLE, Md., May 24, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company not filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the “Form 10-Q”), which serves as an additional basis for delisting the Company's securities from Nasdaq, and that the Nasdaq Hearings Panel will consider this matter in connection with the continued listing of the Company's securities on Nasdaq. Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all periodic reports with the Securities and Exchange Commission (the “SEC”).
OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q
ROCKVILLE, Md., May 24, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company not filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the “Form 10-Q”), which serves as an additional basis for delisting the Company's securities from Nasdaq, and that the Nasdaq Hearings Panel will consider this matter in connection with the continued listing of the Company's securities on Nasdaq. Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all periodic reports with the Securities and Exchange Commission (the “SEC”).
05/16 07:00 EST - globenewswire.com
OpGen Announced 1-for-10 Reverse Stock Split
ROCKVILLE, Md., May 16, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) today announced that the Company's board of directors has approved a 1-for-10 reverse stock split of its shares of common stock (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 12:01 a.m. EST on May 20, 2024 and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis under the Company's existing trading symbol “OPGN.” The new CUSIP number for the Company's common stock following the Reverse Stock Split will be 68373L505.
OpGen Announced 1-for-10 Reverse Stock Split
ROCKVILLE, Md., May 16, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) today announced that the Company's board of directors has approved a 1-for-10 reverse stock split of its shares of common stock (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 12:01 a.m. EST on May 20, 2024 and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis under the Company's existing trading symbol “OPGN.” The new CUSIP number for the Company's common stock following the Reverse Stock Split will be 68373L505.
04/29 16:05 EST - globenewswire.com
OpGen Provides Update on Business Operations and Strategic Opportunities
ROCKVILLE, Md., April 29, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it entered into an agreement to sell its commercial customer contracts and installed base of Unyvero systems to Camtech Pte Ltd (“Camtech”), a Singaporean family office for $218,000. The transaction follows Camtech's prior acquisition of all of Curetis GmhH's (“Curetis”), the Company's subsidiary, Unyvero assets, rights and businesses, as part of Curetis' insolvency proceedings.
OpGen Provides Update on Business Operations and Strategic Opportunities
ROCKVILLE, Md., April 29, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it entered into an agreement to sell its commercial customer contracts and installed base of Unyvero systems to Camtech Pte Ltd (“Camtech”), a Singaporean family office for $218,000. The transaction follows Camtech's prior acquisition of all of Curetis GmhH's (“Curetis”), the Company's subsidiary, Unyvero assets, rights and businesses, as part of Curetis' insolvency proceedings.
04/23 16:15 EST - globenewswire.com
OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K
ROCKVILLE, Md., April 23, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company not filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Form 10-K”). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all periodic reports with the Securities and Exchange Commission (the “SEC”). The Company previously filed a Form 12b-25 with the SEC disclosing that it was unable to file the Form 10-K by April 1, 2024 without unreasonable effort or expense.
OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K
ROCKVILLE, Md., April 23, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company not filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Form 10-K”). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all periodic reports with the Securities and Exchange Commission (the “SEC”). The Company previously filed a Form 12b-25 with the SEC disclosing that it was unable to file the Form 10-K by April 1, 2024 without unreasonable effort or expense.
03/25 16:05 EST - globenewswire.com
OpGen Announces Acquisition of Preferred Stock by David Lazar
ROCKVILLE, Md., March 25, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), announced today that the Company entered into a securities purchase agreement with David E. Lazar, an experienced private investor, pursuant to which he will acquire 3,000,000 shares of Series E Convertible Preferred Stock (“Series E Preferred Stock”) of the Company at a price of $1.00 per share for aggregate gross proceeds of $3.0 million. The proceeds of the transaction will be used to repay and settle outstanding indebtedness and liabilities of the Company and for other general corporate and operating purposes.
OpGen Announces Acquisition of Preferred Stock by David Lazar
ROCKVILLE, Md., March 25, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), announced today that the Company entered into a securities purchase agreement with David E. Lazar, an experienced private investor, pursuant to which he will acquire 3,000,000 shares of Series E Convertible Preferred Stock (“Series E Preferred Stock”) of the Company at a price of $1.00 per share for aggregate gross proceeds of $3.0 million. The proceeds of the transaction will be used to repay and settle outstanding indebtedness and liabilities of the Company and for other general corporate and operating purposes.
11/14 16:30 EST - globenewswire.com
OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update
ROCKVILLE, Md., Nov. 14, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its third quarter 2023 financial and operating results.
OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update
ROCKVILLE, Md., Nov. 14, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its third quarter 2023 financial and operating results.
10/12 12:32 EST - globenewswire.com
OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross Proceeds
ROCKVILLE, Md., Oct. 12, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that it has entered into an agreement with an institutional investor that is an existing holder of warrants to purchase common shares of the Company for cash (the “Existing Warrants”), wherein the investor agreed to exercise the Existing Warrants to purchase up to a maximum of 10,892,728 common shares at an exercise price of $0.7785 per share. As part of the agreement, the existing holder has agreed to pay an additional $0.25 consideration per share, resulting in gross proceeds of up to approximately $11.2 million, assuming full exercise of the existing warrants and before deducting offering fees and expenses.
OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross Proceeds
ROCKVILLE, Md., Oct. 12, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that it has entered into an agreement with an institutional investor that is an existing holder of warrants to purchase common shares of the Company for cash (the “Existing Warrants”), wherein the investor agreed to exercise the Existing Warrants to purchase up to a maximum of 10,892,728 common shares at an exercise price of $0.7785 per share. As part of the agreement, the existing holder has agreed to pay an additional $0.25 consideration per share, resulting in gross proceeds of up to approximately $11.2 million, assuming full exercise of the existing warrants and before deducting offering fees and expenses.
10/12 07:57 EST - investorplace.com
Why Is OpGen (OPGN) Stock Up 540% Today?
OpGen (NASDAQ: OPGN ) stock is undergoing a massive rally on Thursday following a couple of pieces of news from the precision medicine company. The first bit of news worth mentioning is a progress update on a product sale.
Why Is OpGen (OPGN) Stock Up 540% Today?
OpGen (NASDAQ: OPGN ) stock is undergoing a massive rally on Thursday following a couple of pieces of news from the precision medicine company. The first bit of news worth mentioning is a progress update on a product sale.
09/29 08:22 EST - investorplace.com
Why Is OpGen (OPGN) Stock Up 115% Today?
OpGen (NASDAQ: OPGN ) stock is on the rise Friday after the precision medicine company withdrew a share offering. A filing with the Securities and Exchange Commission (SEC) has the company requesting the withdrawal of its Registration Statement on Form S-1.
Why Is OpGen (OPGN) Stock Up 115% Today?
OpGen (NASDAQ: OPGN ) stock is on the rise Friday after the precision medicine company withdrew a share offering. A filing with the Securities and Exchange Commission (SEC) has the company requesting the withdrawal of its Registration Statement on Form S-1.
08/10 19:17 EST - seekingalpha.com
OpGen, Inc. (OPGN) Q2 2023 Earnings Call Transcript
OpGen, Inc. (NASDAQ:OPGN ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Oliver Schacht - President and CEO Albert Weber - Chief Financial Officer Conference Call Participants Operator Welcome to OpGen's Second Quarter 2023 Earnings Call and Business Update. Before we turn the call over to OpGen management, please note that any forward-looking statements made during this call are based on management's current expectations and observations and are subject to risks and uncertainties that could cause actual results to differ from the forward-looking statements.
OpGen, Inc. (OPGN) Q2 2023 Earnings Call Transcript
OpGen, Inc. (NASDAQ:OPGN ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Oliver Schacht - President and CEO Albert Weber - Chief Financial Officer Conference Call Participants Operator Welcome to OpGen's Second Quarter 2023 Earnings Call and Business Update. Before we turn the call over to OpGen management, please note that any forward-looking statements made during this call are based on management's current expectations and observations and are subject to risks and uncertainties that could cause actual results to differ from the forward-looking statements.
08/10 16:15 EST - globenewswire.com
OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update
ROCKVILLE, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its second quarter and first half of 2023 financial and operating results. Management will host an investor call to discuss quarterly results and provide a business update.
OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update
ROCKVILLE, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its second quarter and first half of 2023 financial and operating results. Management will host an investor call to discuss quarterly results and provide a business update.
08/07 07:30 EST - globenewswire.com
OpGen's Subsidiary Ares Genetics Releases New Features to its AREScloud Offering
ROCKVILLE, Md., Aug. 07, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, and OpGen subsidiary, Ares Genetics, which strives to become a leader in bacterial genomics and AI-powered prediction of antimicrobial resistance (AMR), announced today a major feature upgrade for the AREScloud platform that has been implemented with our healthcare clients to enhance genomic surveillance.
OpGen's Subsidiary Ares Genetics Releases New Features to its AREScloud Offering
ROCKVILLE, Md., Aug. 07, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, and OpGen subsidiary, Ares Genetics, which strives to become a leader in bacterial genomics and AI-powered prediction of antimicrobial resistance (AMR), announced today a major feature upgrade for the AREScloud platform that has been implemented with our healthcare clients to enhance genomic surveillance.
08/03 08:00 EST - globenewswire.com
OpGen's Subsidiary Curetis and FIND Extend R&D Collaboration Agreement
ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today that its German subsidiary Curetis GmbH has signed an extended and continued research and development (“R&D”) collaboration agreement with FIND. Following the successful completion of the feasibility phase of the collaboration and having met all milestones on time and within budgets, the parties now plan to collaborate on first phases of product development of an antimicrobial resistance (AMR) cartridge from blood culture that is tailored to the needs of low- and middle-income countries (LMICs) in terms of panel design and coverage of specific genetic variants of bacterial strains and their AMR markers in such countries, as well as ensuring attractive cost profile and pricing models that allow for access to such rapid testing in LMICs.
OpGen's Subsidiary Curetis and FIND Extend R&D Collaboration Agreement
ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today that its German subsidiary Curetis GmbH has signed an extended and continued research and development (“R&D”) collaboration agreement with FIND. Following the successful completion of the feasibility phase of the collaboration and having met all milestones on time and within budgets, the parties now plan to collaborate on first phases of product development of an antimicrobial resistance (AMR) cartridge from blood culture that is tailored to the needs of low- and middle-income countries (LMICs) in terms of panel design and coverage of specific genetic variants of bacterial strains and their AMR markers in such countries, as well as ensuring attractive cost profile and pricing models that allow for access to such rapid testing in LMICs.
08/03 07:30 EST - globenewswire.com
OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time
ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter 2023 financial results after the close of the U.S. financial markets on Thursday, August 10th 2023. OpGen's management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide an update on business activities.
OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time
ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter 2023 financial results after the close of the U.S. financial markets on Thursday, August 10th 2023. OpGen's management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide an update on business activities.
07/19 07:30 EST - globenewswire.com
OpGen's Subsidiary Curetis Meets Milestones of Extended and Expanded R&D Collaboration with FIND
ROCKVILLE, Md., July 19, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today that its German subsidiary Curetis GmbH has met all milestones under its extended and expanded research and development (“R&D”) collaboration agreement with FIND. Following the delivery of a comprehensive milestone report at the end of the second quarter of 2023, FIND recently confirmed that all requirements have been met successfully.
OpGen's Subsidiary Curetis Meets Milestones of Extended and Expanded R&D Collaboration with FIND
ROCKVILLE, Md., July 19, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today that its German subsidiary Curetis GmbH has met all milestones under its extended and expanded research and development (“R&D”) collaboration agreement with FIND. Following the delivery of a comprehensive milestone report at the end of the second quarter of 2023, FIND recently confirmed that all requirements have been met successfully.
07/06 09:20 EST - zacks.com
Buy 5 Top-Ranked Stocks With Rising P/E in July
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include OpGen (OPGN), Adaptimmune Therapeutics (ADAP), Valmont Industries (VMI), Versus Systems (VS) and Tradeweb Markets (TW).
Buy 5 Top-Ranked Stocks With Rising P/E in July
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include OpGen (OPGN), Adaptimmune Therapeutics (ADAP), Valmont Industries (VMI), Versus Systems (VS) and Tradeweb Markets (TW).
06/21 07:18 EST - zacks.com
Bet on DuPont Analysis to Pick 5 Stocks for Stellar Returns
Do you have more faith in DuPont analysis than simple ROE calculation? Tap PDD Holdings Inc. (PDD), OpGen (OPGN), AGCO (AGCO), A10 Networks (ATEN) and The Duckhorn Portfolio (NAPA).
Bet on DuPont Analysis to Pick 5 Stocks for Stellar Returns
Do you have more faith in DuPont analysis than simple ROE calculation? Tap PDD Holdings Inc. (PDD), OpGen (OPGN), AGCO (AGCO), A10 Networks (ATEN) and The Duckhorn Portfolio (NAPA).
06/05 09:10 EST - zacks.com
Go Beyond Bargain Hunting; Buy 5 Stocks With Rising P/E
Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include OpGen (OPGN), The RealReal (REAL), Trevena (TRVN), ChargePoint (CHPT) and Caterpillar (CAT).
Go Beyond Bargain Hunting; Buy 5 Stocks With Rising P/E
Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include OpGen (OPGN), The RealReal (REAL), Trevena (TRVN), ChargePoint (CHPT) and Caterpillar (CAT).